Chemomab Therapeutics Ltd.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Aug 19, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Planned Phase 2 study overview
Planned Phase 2 study overview
Together with Scipher, we expect to complete pre-IND activities and submit an IND in 2026; The combined company expect to obtain IND approval and begin Phase 2 recruitment in the first half of 2027; complete enrollment during the second half of 2027; and report 12-week Phase 2 data in the first half of 2028. If successful, the Phase 2 readout is expected to be a key clinical catalyst for the combined company, providing evidence of initial efficacy and safety in patients with RA, as well as nebokitug biomarker data in a precision medicine-selected RA population.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.